The Online Investor
Catalyst Biosciences Inc (CBIO)

Catalyst Biosciences is a clinical-stage biopharmaceutical company focused on developing medicines to address hematology indications, including the treatment of hemophilia. Co. is focusing its product development efforts in the fields of hemostasis (the process that regulates bleeding). Co.'s principal product candidate is marzeptacog alfa (activated), a Factor VIIa variant. Marzeptacog alfa (activated) is being developed for the prophylactic treatment of individuals with hemophilia A and B with inhibitors. Co.'s second product candidate is CB 2679d/ISU304, a subcutaneously dosed Factor IX drug for the prophylactic treatment of individuals with hemophilia B.

CBIO SEC Filing Email Alerts Service
Company Name: 
Catalyst Biosciences Inc
Drugs & Pharmaceuticals
Number of ETFs Holding CBIO: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 
Quotes delayed 20 minutes

Buy (3.00 out of 4)
40th percentile
(ranked lower than approx. 60% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Catalyst Biosciences Inc (CBIO) Page | The Online Investor Page |

Copyright © 1998 - 2019, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.